- Home
- » Tags
- » Azacitidine
Top View
- Vidaza, INN-Azacitidine
- Cyclophosphamide Use CAS No
- VIDAZA® (Azacitidine for Injection) Rx Only
- Bc Cancer Chemotherapy Preparation and Stability
- A Phase 2 Study of Combination Therapy with Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Myelodysplastic Syndromes Or Secondary Acute Myeloid Leukemia
- Subcutaneous Administration of Anticancer Agents
- Hydroxyurea [CAS No
- NCCN Guidelines for Acute Myeloid Leukemia V.3.2018 – Follow-Up – November 28, 2018
- Revised Policy Guidelines for Azacitidine (Vidaza) in This Issue
- Diamminedichloroplatinum in Malignant Mesothelioma1
- Emerging Drugs for Prostate Cancer
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Phase 1B Study of IGF-Methotrexate Conjugate in the Treatment of High-Grade Myelodysplastic Syndromes HASSAN B
- Vidaza, INN-Azacitidine
- A Multi-Centre Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukaemia
- Characterization and Targeting of Malignant Stem Cells in Patients with Advanced Myelodysplastic Syndromes
- Leukemia Insights Spring 2011
- Emetogenic Potential of Antineoplastic Agents
- Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed Or Refractory AML Or MDS
- Pevonedistat, a First-In-Class NEDD8-Activating Enzyme Inhibitor, Combined with Azacitidine in Patients With
- Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches
- Assessment Report
- AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
- Cladribine Combined with Low-Dose Cytarabine As Frontline Treatment
- Phase I Study of Azacitidine and Oxaliplatin in Patients with Advanced Cancers That Have Relapsed Or Are Refractory to Any Plati
- Randomized Phase-II Trial Evaluating Induction Therapy with Idarubicin and Etoposide Plus Sequential Or Concurrent Azacitidine A
- These Highlights Do Not Include All the Information Needed to Use VIDAZA Safely and Effectively. See Full Prescribing Information for VIDAZA
- THE MDS NEWS the Newsletter of the Myelodysplastic Syndromes Foundation from the Guest 1
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Guidelines for the Diagnosis and Treatment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Nordic MDS Group
- Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable
- (Arsenic Trioxide) in the Treatment of Myelodysplastic Syndromes
- Hydroxycarbamide for Acute Myeloid Leukaemia (AML)
- Staying on Track in a Rapidly Changing Treatment Landscape
- 5-Azacitidine for Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation
- (Vidaza®) in Pediatric Patients with Newly Diagnosed Or Relapsed High-Grade Pediatric MDS Or JMML
- Hypomethylating Chemotherapeutic Agents As Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
- LWWUS MPH Jpho-13-270 322..324
- Pharmacologic Induction of Innate Immune Signaling Directly Drives Homologous Recombination Deficiency
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- EMEA/593162/2008 ASSESSMENT REPORT for VIDAZA International
- The Effect of Two Nucleoside Antitumor Drugs on the Proliferation and DNA Methylation of Human Gastric Cancer Cells
- A Patient's Guide to VIDAZA®
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is Not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
- Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer
- The Antimetabolites
- Assessment Report
- Hikma Launches Azacitidine for Injection
- A Phase 1 Study of Azacitidine with High-Dose Cytarabine and Mitoxantrone in High-Risk Acute Myeloid Leukemia
- Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections Valerie W. C. Soo1£, Brian W. Kwan 1£, Héctor Queza
- Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
- Revised MRP of Non-Scheduled Anti-Cancer Medicines W.E.F. 08.03.2019 (Based on Data Received Till 07.03.2019) Annexure : X Sl
- Hazardous Drug List
- Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis After Cord Blood Transplantation
- Medications That Are Considered Hazardous
- Azacitidine for Acute Myeloid Leukaemia (AML)
- Azacitidine in the Treatment of Extramedullary Relapse of AML After Allogeneic Hematopoietic Cell Transplantation
- University of Illinois Cancer Center Confidential AML-02: Study of the Activity and Safety of the Addition of Omacetaxine To
- Azacitidine and Donor Lymphocyte Infusions As First Salvage Therapy For
- Antineoplastic Drugs
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML